Health authorities of Peru have approved a Phase 3 clinical trial for a potential COVID-19 vaccine developed by China National Biotec Group (CNBG), the company said on Thursday in Chinese social media platform Weibo.

The experimental vaccine of CNBG, a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), has already entered Phase 3 testing in United Arab Emirates.

Phase 3 trials, which usually involve several thousand participants, allow researchers to gather data on the efficacy of potential vaccines for final regulatory approvals.